Community Regional Cancer Center

Indianapolis, Indiana 46256

0 studies enrolling now · 16 studies all time

What they study most

Breast Cancer, Colorectal Cancer, Esophageal Cancer, Lung Cancer, Lymphoma, Non-Hodgkin, Malignant Neoplasm of Breast, Metastatic Breast Cancer, Multiple Myeloma, Non-Small Cell Lung Cancer, Prostate Cancer, Renal Cell Carcinoma, Small Cell Lung Cancer

Studies at this site

• PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations — Completed
• Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma — Stopped early
• Randomized Controlled Trial of Genomically Directed Therapy in Patients With Triple Negative Breast Cancer — Completed
• BNC105P in Combination With Everolimus/Following Everolimus For Progressive Metastatic Clear Cell Renal Cell Carcinoma — Completed
• Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma — Stopped early
• Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer — Completed
• Cetuximab and Radiation Therapy for Surgically Resectable Esophageal and Gastroesophageal (GE) Junction Carcinomas — Completed
• Pemetrexed and Radiation for Poor-Risk Stage III Non-Small Cell Lung Cancer — Stopped early
• Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer — Completed
• Erlotinib + Bevacizumab for PS 2 Chemotherapy Naïve Non-Small Cell Lung Cancer — Completed
• Capecitabine and Oxaliplatin in Treating Patients With Metastatic Breast Cancer — Completed
• A Correlative Study for Predicting Response and Toxicity in Patients Receiving Chemotherapy for Breast Cancer — Stopped early
• Phase I/Randomized Phase II Study of Second Line Therapy With Irinotecan + Cetuximab +/- RAD001 for Colorectal Cancer — Completed
• A Study of Paclitaxel Plus Bevacizumab in Patients With Chemosensitive Relapsed Small Cell Lung Cancer — Completed
• Pemetrexed in Patients With Chemosensitive and Chemoresistant Relapsed Small Cell Lung Cancer — Stopped early
• Capecitabine, Oxaliplatin and Trastuzumab in Treating Patients With HER2 Positive Metastatic Breast Cancer — Stopped early